Tokai Pharmaceuticals is focused on developing novel, proprietary treatments for prostate cancer and other hormonally-driven cancers. The company's lead drug candidate, galeterone (TOK-001), is currently being evaluated in a Phase 2 study, ARMOR2, in patients with castration resistant prostate cancer (CRPC).  In addition, Tokai is exploring a pipeline of new indications for galeterone, including hormone sensitive prostate cancer, as well as breast cancer. Galeterone may be administered as a single agent or in combination therapy.